13F Holdings
中文EN

TRLV Trulieve Cannabis Corp.

Medicinal Chemicals & Botanical Products · NYSE · SEC CIK 1754195 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-9.1%
TTM net income YoY-218.5%
TTM EPS YoY-245.5%
Revenue 3-yr CAGR-1.8%
Net income 3-yr CAGR—

Margins

Gross margin60.6%
Operating margin-25.6%
Net margin-41.3%
FCF margin16.2%
EBITDA margin-16.1%

Returns

ROE-45.2%
ROA-17.7%
ROIC (approx.)-24.8%
Asset turnover0.43x

Leverage & solvency

Liabilities / assets63.6%
Debt / equity0.25x
Current ratio5.52x
Interest coverage-5.25x

Cash quality & payout

Operating cash flow / net income-0.54x
Accruals ratio-27.2%
Payout ratio—
Capex / revenue6.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY2025*2025-12-31FY2024*2024-12-31FY2023*2023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$1.18B$1.19B$1.13B$1.22B$931.93M
Cost of revenue$470.01M$470.75M$540.57M$529.10M$365.36M
Gross profit$711.17M$715.75M$588.63M$689.13M$566.57M
SG&A expense$445.21M$510.45M$386.16M$169.47M$99.46M
Operating income$143.50M$97.78M-$221.61M$50.16M$204.05M
Interest expense$63.45M$62.19M$81.57M$73.42M$29.12M
Pretax income$91.47M$42.71M-$284.54M-$19.24M$176.25M
Income tax$208.11M$197.59M$151.36M$163.38M$145.72M
Net income-$116.38M-$155.10M-$527.99M-$252.73M$17.45M
EBITDA$261.13M$210.59M-$111.79M$166.55M$249.84M
EPS (basic)-0.58-0.79-2.28-0.950.22
EPS (diluted)-0.58-0.79-2.28-0.950.21
Weighted avg. shares (diluted)191.32M189.99M188.97M188.00M146.76M
Banking
Loans, net——$13.70M$12.70M—
Balance sheet
Cash & equivalents$255.53M$238.80M$201.37M$207.19M$226.63M
Short-term investments$0$60.39M$0——
Receivables$10.50M$8.29M$6.70M$6.51M$8.85M
Inventory$242.30M$231.37M$213.12M$276.50M$212.19M
Current assets$562.72M$604.56M$477.35M$593.54M$524.42M
PP&E, net$670.44M$716.05M$676.35M$743.26M$779.92M
Goodwill$483.90M$483.90M$483.90M$791.50M$765.36M
Intangibles$798.37M$859.48M$917.19M$984.80M$1.12B
Total assets$2.70B$2.87B$2.73B$3.40B$3.41B
Current liabilities$126.94M$138.49M$114.85M$210.29M$168.94M
Long-term debt$136.74M$364.84M$363.21M$541.66M$462.93M
Total debt$136.74M$364.84M$363.21M$541.66M$462.93M
Total liabilities$1.55B$1.62B$1.32B$1.47B$1.26B
Shareholders' equity$1.16B$1.26B$1.41B$1.93B$2.15B
Net debt-$118.79M$126.03M$161.84M$334.48M$236.30M
Shares outstanding192.31M191.01M186.24M185.99M180.50M
Cash flow statement
Operating cash flow$272.82M$271.48M$201.84M$23.10M$12.90M
Capital expenditure$44.19M$122.60M$40.24M$164.75M$275.90M
Free cash flow$228.63M$148.88M$161.60M-$141.65M-$263.00M
Investing cash flow$13.50M-$206.62M-$37.47M-$215.06M-$215.18M
Financing cash flow-$270.50M-$33.44M-$175.59M$177.80M$289.23M
Depreciation & amortization$117.63M$112.81M$109.83M$116.38M$45.79M
Stock-based compensation$20.47M$20.20M$10.57M$18.12M$9.25M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.